Hormona Wins a Global Recognition Award 2026
A woman in her mid-thirties has spent two years describing the same cluster of symptoms to three different doctors: fatigue, mood instability, disrupted sleep, and irregular cycles. Each consultation ends with a normal blood test result and a referral to a mental health service. What she has is a hormonal imbalance, measurable and manageable. Still, the clinical tools to identify it have never reached her without a lab, a needle, and a waiting period measured in days. Hormona was built to close that gap and to deliver clinical-grade at-home hormone testing to women across 185 countries, with 2 million-plus data points already collected at the seed stage. It has earned a 2026 Global Recognition Award.
Technical Innovation and Architecture
Hormona‘s hormone test uses proprietary nanoshell lateral flow immunoassay technology embedded in a urine test strip, designed to fully quantify hormone levels across the complete clinical range rather than delivering a binary positive or negative output. The user collects a first-morning urine sample, applies the strip, and scans it through the Hormona app’s integrated smartphone camera, which processes the image using a proprietary AI algorithm trained on 2 million-plus longitudinal data points from users worldwide, delivering a quantitative hormone level result in 15 minutes with no blood draw, no additional reader hardware, and no lab visit. This architecture converts the smartphone already in every user’s pocket into a clinical-grade immunoassay analyzer, removing the cost and friction barriers that have historically kept diagnostic-quality hormone testing inside clinical settings.
The AI engine operates on two analytical tracks simultaneously: retrospective pattern recognition that builds an individual hormone profile from cycle-to-cycle tracking data, and prospective symptom prediction that forecasts which symptoms a user is likely to experience before they occur, based on her personal hormonal data. The model improves continuously as users log symptoms, complete tests, and track cycles, creating a feedback loop between adoption and accuracy that deepens predictive capability at scale. No competitor currently delivers quantitative, non-invasive at-home hormone measurement integrated with an AI prediction layer in a single 15-minute workflow.
Market Strategy and Leadership
CEO Karolina Löfqvist brings management consulting experience from Valcon and financial services experience from Fisher Investments, combined with a personal multi-year diagnostic journey through hormonal health issues that went undiagnosed despite extensive medical consultations. Co-Founder and COO Jasmine Tagesson manages operations and partnerships across a platform already live in 185 countries at the seed stage. The founding team’s Swedish-British background, with headquarters in London and investor relationships spanning Helsinki, London, Brussels, Stockholm, and the US, reflects deliberate access to both progressive Nordic femtech infrastructure and the UK’s established healthtech capital market.
The $6.7 million oversubscribed seed round, led by Voima Ventures and co-led by Supernode Global VC, with participation from DLF Ventures, Nascent Invest, and Techstars, brings total funding to over $11 million and funds three specific objectives: global launch of the at-home hormone test kit, a dedicated perimenopause app, and international market expansion. The dual revenue model, combining app subscriptions with recurring test kit consumable purchases usable exclusively within the Hormona ecosystem, creates a hardware-software lock-in dynamic that protects user retention more effectively than content or features alone. Editorial coverage across Vogue, Forbes, BBC News, CNN, Wired, and Marie Claire drives organic user acquisition at a cost-per-user that paid digital marketing cannot replicate proportionally.
Industry Impact and Future Vision
Hormona’s impact addresses one of healthcare’s most documented structural failures: the consistent underdiagnosis of women’s hormonal conditions across every healthcare system globally, with 80% of women experiencing hormone-related symptoms and most waiting years for an accurate diagnosis. Each Hormona test delivers data that would require a GP referral, a venipuncture appointment, and a laboratory processing period to produce, and it does so in the user’s home in 15 minutes, for $97 billion by 2030, with AI-powered hormone-tracking positioned as a primary growth driver at a fraction of the cost. Across 185 countries, the platform already reaches women in geographies where the conventional hormonal diagnostic pathway is structurally inaccessible.
The roadmap advances into perimenopause-specific tracking, additional hormone biomarkers beyond estrogen, B2B corporate wellness and health insurance partnerships, and deeper AI personalization as the longitudinal dataset continues to grow. The femtech market will expand from $60 billion in 2024 to $97 billion by 2030, with AI-powered hormone-tracking positioned as a primary growth driver along that trajectory. Hormona earns the 2026 Global Recognition Award for building the clinical-grade, non-invasive hormonal health platform that 80% of women globally need, and no incumbent technology provider has yet delivered.
Proprietary nanoshell lateral flow immunoassay technology quantifies hormone levels across the full clinical range from a urine test strip scan, delivering results that conventional at-home tests cannot produce without laboratory processing
Smartphone camera functions as the optical immunoassay reader, eliminating the need for dedicated hardware and removing the cost barrier that has historically blocked clinical-grade diagnostics from mass-market consumer adoption
AI algorithm trained on 2 million-plus longitudinal data points from 185 countries processes test strip images and delivers personalized quantitative hormone level results in 15 minutes
Prospective symptom prediction engine forecasts which symptoms a user is likely to experience before onset, based on her individual hormonal profile built from accumulated cycle and test data
Dual analytical architecture: retrospective pattern recognition for hormone profile building plus prospective prediction for symptom forecasting, both operating within a single app session
Test kit works exclusively with the Hormona app, creating platform lock-in that increases data collection, model accuracy, and user retention simultaneously with each test completed
Results delivered in 15 minutes from urine sample collection, compared to 5-7 days for mail-in blood spot tests (Everlywell) and days-to-weeks for clinical laboratory referral pathways
$6.7 million seed round closed oversubscribed in May 2025, led by Voima Ventures (deeptech VC) and co-led by Supernode Global VC, bringing total funding to over $11 million
2 million-plus data points collected from users across 185 countries at seed stage, providing a longitudinal hormonal health training dataset that new entrants cannot replicate without years of equivalent user acquisition
Platform available on iOS and Android globally, with App Store and Google Play distribution providing immediate access to international user bases without distribution infrastructure investment
Techstars alumni status, with a global acceptance rate of approximately 1%, provides operational mentorship, investor credibility, and network access at a level that cannot be purchased
Startups.co.uk Top 100 2025 inclusion provides independent editorial validation of Hormona’s position within the UK startup ecosystem
Total funding of over $11 million across seed and pre-seed rounds, with an oversubscribed final seed confirming investor demand that exceeded available allocation
Voima Ventures, a deeptech-focused Finnish VC, led the seed round; deeptech lead investors evaluate technology defensibility rather than only market size, validating Hormona’s nanoshell and AI architecture as technically proprietary
Investor syndicate spans five organizations across four countries: Voima Ventures (Finland), Supernode Global VC (UK), DLF Ventures (Belgium), Nascent Invest (Sweden), and Techstars (US), providing geographic market intelligence and partnership networks across three continents
Media coverage across Vogue, Forbes, BBC News, CNN, Wired, and Marie Claire creates an organic acquisition channel that no femtech competitor has replicated at equivalent brand recognition
B2B expansion into corporate wellness programs and health insurance partnerships is structured as the next scaling layer, converting individual user data into enterprise health intelligence products
The femtech market is projected to grow from $60 billion in 2024 to $97 billion by 2030, with hormone tracking and AI-enabled diagnostics identified as among the highest-growth segments within that expansion
Three-step test workflow: collect first-morning urine sample, apply strip, scan with smartphone camera; no blood draw, no additional equipment, no lab appointment required
Results integrate directly into the Hormona app alongside cycle tracking data, symptom logs, and AI predictions, providing context for each hormone measurement within the user’s complete health timeline
Subscription tiers from $2.99 per month to $59.99 per year make personalized hormonal health monitoring accessible across income levels without requiring commitment to clinical consultation costs
Support across every reproductive life stage: first period, reproductive years, perimenopause transition, and menopause, with a dedicated perimenopause app in development
Expert-backed content library, nutrition recommendations, mindfulness sessions, recipes, and community forum within the app reduce the need for external consultation while maintaining clinical oversight
Urine-based non-invasive testing eliminates single-use needles, blood collection materials, cold-chain laboratory shipping, and hazardous biological waste associated with blood-based hormone diagnostics, reducing the per-test environmental footprint
185-country user base at seed stage confirms that the platform serves women in geographies where clinical hormone testing is structurally inaccessible, extending diagnostic equity beyond healthcare systems with well-funded laboratory infrastructure
Founding thesis directly addresses the systemic underdiagnosis of hormonal conditions in women, a documented healthcare equity gap confirmed by 80% prevalence of hormone-related symptoms against low rates of accurate clinical diagnosis
Privacy architecture treats women’s reproductive and hormonal health data as a sensitive category requiring active protection, with privacy policy publicly available and data handling commitments built into the product’s core value proposition
Eliminating clinical consultation requirements for initial hormonal data collection reduces unnecessary GP appointment demand, lowering the load on healthcare systems while expanding the information available to clinicians when consultations do occur
